Evommune, Inc.

About Evommune, Inc.

Evommune is a biotechnology company focused on discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases, aiming to address the root causes of inflammation and improve lives.

Products & Services

MRGPRX2 Antagonist (EVO756):An oral inhibitor targeting chronic inducible urticaria and atopic dermatitis, currently in Phase 2 clinical trials.

IL-18 Fusion Protein:A product candidate in development for chronic inflammatory diseases.

Specialties

Chronic Inflammatory Diseases MRGPRX2 Inhibition IL-18 Fusion Proteins Clinical Trials for Inflammatory Conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 172500000 MR: - FA: $172.5 million FAN: 172500000	D: 2025-11-07 FD: 2025-11-07	4 investors
2	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2025-11-05 FD: 2025-11-05	4 investors
3	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 150000000 MR: - FA: $150,000,000 FAN: 150000000	D: 2025-10-30 FD: 2025-10-30	4 investors
4	RT: Series C T: - FT: Series C	A: 115000000 MR: - FA: 115 million FAN: 115000000	D: 2024-10-31 FD: 2024-10-31	18 investors
5	RT: Series B T: - FT: Series B	A: 57500000 MR: - FA: $57.5 million FAN: 57500000	D: 2023-06-28 FD: 2023-06-28	1 investors
6	RT: Series B T: - FT: Series B	A: 50000000 MR: - FA: 50 Million FAN: 50000000	D: 2023-04-26 FD: 2023-04-26	6 investors

Initial Public Offering (IPO) Latest

2025-11-07

$172.5M

4 investors (Pro only)

Initial Public Offering (IPO) 2025-11-05

$150.0M

Initial Public Offering (IPO) 2025-10-30

$150.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Luis Peña

President & Chief Executive Officer

E

Eugene A. Bauer

Chief Medical Officer

LinkedIn (Pro only)

K

Kyle Carver

Chief Financial Officer

LinkedIn (Pro only)

G

Gregory S. Moss

Chief Business and Legal Officer

J

Jeegar Patel

Chief Scientific Officer

J

Janice Drew

Executive Vice President, Operations

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

Evommune, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised